TORONTO, May 13, 2024
/CNW/ - Auxly Cannabis Group Inc. (TSX: XLY) (OTCQB:
CBWTF) ("Auxly" or the "Company") a leading
consumer packaged goods company in the cannabis products market,
today released its financial results for the three months ended
March 31, 2024. These filings and additional information
regarding Auxly are available for review on SEDAR at
www.sedar.com.
Q1 2024 Highlights and Subsequent Events
- Auxly achieved its best Q1 in its history across key metrics of
revenue, margin and adjusted EBITDA;
- Record net revenues for a fiscal Q1 of $25.2 million, an increase of 5% compared to the
same period in 2023;
- Achieved Gross Margin on Finished Cannabis Inventory
Sold1 of 38% in the quarter, a record for historical Q1
periods;
- Record Adjusted EBITDA1 for a fiscal Q1 of
$2.2 million, an improvement of
1,523% or $2.1 million
year-over-year;
- Continued reductions in SG&A through ongoing efforts to
decrease overhead costs, resulting in an 11% decline
quarter-over-quarter and a 15% decline compared to the same period
in 2023;
- Further strengthened its balance sheet with the Imperial Brands
plc conversion of over $123 million
of debt into shares, resulting in 19.8% ownership of the Company
and completed the extension of the Auxly Leamington credit facility
between its syndicate of lenders led by BMO to December 31, 2025 with an option to extend a
further year by making a $2.5 million
principal repayment;
- Maintained its top 10 LP position in Canada by share of market based on total
recreational retail sales, securing the #6 LP position with 5% of
the total market2;
- Maintained its leadership position in the competitive vapour
category, while continuing to hold the top four all-in-one SKU
positions in Ontario3
with its Back Forty all-in-ones for three consecutive months;
- Back Forty remains the #1 non-infused pre-roll brand in
Ontario3, with only
seven SKUs currently listed, and has quickly become a consumer
favourite brand in dried flower, ranking #6 in national sales after
seeing a boost with its recently launched strain, Liquid
Imagination;
- Subsequent to quarter end, the Company expanded its branded
product offering to the province of Quebec, with its products now available in all
Canadian provinces as well as the Northwest Territories and Yukon.
- Subsequent to quarter end, the Company introduced its advanced,
fully automated for precision, 0.75g three pack pre-rolls under its
Back Forty brand. These three packs use Auxly's latest top
performing cultivar, Liquid Imagination, that was developed at
Auxly Leamington's advanced greenhouse.
___________________________________
|
1
|
Non-IFRS or
supplementary financial measure. Refer to the Non-GAAP Measures
section in the MD&A for definitions.
|
2
|
Hifyre IQ, as of March
2024
|
3
|
Ontario Cannabis Store
Data, as of March 2024
|
Financial Highlights and Key
Performance Indicators
|
|
|
|
|
For the three months
ended:
|
March
31,
|
March 31,
|
|
|
(000's)
|
2024
|
2023
|
Change
|
% Change
|
Net revenues
|
$
25,241
|
$
23,968
|
$
1,273
|
5 %
|
Gross margin on
finished cannabis inventory sold*
|
9,569
|
8,943
|
626
|
7 %
|
Gross margin on
finished cannabis inventory sold (%)*
|
38 %
|
37 %
|
1 %
|
3 %
|
Net
income/(loss)
|
(26,012)
|
(10,249)
|
(15,763)
|
-154 %
|
Adjusted
EBITDA*
|
2,240
|
138
|
2,102
|
1523 %
|
Weighted average shares
outstanding
|
1,016,839,478
|
954,014,308
|
62,825,170
|
7 %
|
|
|
|
|
|
|
|
|
|
|
As at:
|
March
31,
|
December 31,
|
|
|
(000's)
|
2024
|
2023
|
Change
|
% Change
|
Cash and
equivalents
|
$
13,079
|
$
15,608
|
$
(2,529)
|
-16 %
|
Total assets
|
260,127
|
261,904
|
(1,777)
|
-1 %
|
Debt*
|
66,078
|
123,579
|
(57,501)
|
-47 %
|
*Non-IFRS or
supplementary financial measure. Refer to the Non-GAAP Measures
section for definitions.
|
Hugo Alves, CEO of Auxly,
commented: "Following a transformative year for Auxly, we have
maintained our positive momentum in the first quarter of 2024 and
are continuing to achieve profitable growth. Q1 2024 was the best
Q1 in Auxly history across key metrics of revenue, gross margin and
adjusted EBITDA. Our commitment to product quality,
innovation and distribution excellence drove our top-line sales
growth year over year; and our continued focus on operational
efficiency and prudent capital management helped us deliver another
quarter of adjusted EBITDA profitability. This is all thanks
to the collective efforts of our talented and dedicated employees,
who work hard every day to make quality products that help our
consumers live happier lives. As we head into summer, we are
excited to offer consumers new and innovative products to enjoy
like our new larger Back Forty 0.75g pre-rolls, which will also be
available to consumers in Quebec.
We look forward to another quarter of sustainable, profitable
growth and, as always, we will remain passionately committed to our
consumers."
Results of Operations
|
|
|
(000's)
Three months
ended:
|
March 31, 2024
|
March 31, 2023
|
Revenues
|
|
|
Revenue from
sales of cannabis products
|
$
38,357
|
$ 37,544
|
Excise taxes
|
(13,116)
|
(13,576)
|
Total Net Revenues
|
25,241
|
23,968
|
|
|
|
Cost of
Sales
Costs of finished cannabis inventory sold
|
15,672
|
15,025
|
Inventory
impairment
|
456
|
673
|
Gross profit/(loss) excluding fair value items
|
9,113
|
8,270
|
|
|
|
Unrealized fair
value gain / (loss) on biological transformation
|
2,773
|
4,247
|
Realized fair
value gain/(loss) on inventory
|
(2,435)
|
(4,639)
|
Gross profit
|
9,451
|
7,878
|
|
|
|
Expenses
|
|
|
Selling, general, and administrative expenses
|
8,621
|
10,090
|
Equity-based
compensation
|
1,927
|
409
|
Depreciation and amortization
|
1,230
|
1,745
|
Interest and
accretion expense
|
6,868
|
5,808
|
Total expenses
|
18,646
|
18,052
|
|
|
|
Other incomes
/ (loss)
|
|
|
Interest and
other income
|
19
|
14
|
Gain/(loss) on settlement of assets and liabilities and other expenses
|
(634)
|
-
|
Foreign exchange gain/(loss)
|
(210)
|
(89)
|
Total other income/(loss)
|
(825)
|
(75)
|
|
|
|
Net income/(loss) before income tax
|
(10,020)
|
(10,249)
|
Income tax
recovery/(expense)
|
(15,992)
|
-
|
Net
income/(loss)
|
$
(26,012)
|
$ (10,249)
|
|
|
|
Adjusted EBITDA
|
$
2,240
|
$
138
|
Net
income/(loss) per common
share (basic and diluted)
|
$
(0.03)
|
$
(0.01)
|
Weighted average
shares outstanding (basic and diluted)
|
1,016,839,478
|
954,014,308
|
Net Revenues
For the period ended March 31,
2024, net revenues were $25.2
million as compared to $24.0
million during the same period in 2023, an increase of 5%.
Revenues for 2023 were comprised of approximately 59% (2023 – 54%)
in sales of dried flower and pre-roll Cannabis Products, with the
remainder from oils and Cannabis 2.0 Product sales. Net
revenues included wholesale bulk flower sales of approximately
$4.2 million during the period.
Approximately 76% (2023 – 85%) of cannabis sales during the period
originated from sales to British
Columbia, Alberta and
Ontario.
Gross Profit
Auxly realized a gross profit of $9.5
million in the first quarter of 2024 resulting in a 37%
Gross Profit Margin, as compared to $7.9
million or 33%, respectively, during the same period in
2023. The Gross Margin on Finished Cannabis Inventory Sold improved
to 38% versus 37% in the same period of 2023 as a result of a
higher proportion of Cannabis 1.0 Products sold, and the
streamlining of Cannabis 2.0 Products and operating costs.
Realized and unrealized fair value gains and losses reflect
accounting treatments associated with Auxly Leamington cultivation
activities and sales and are influenced by changes in production,
sales and net realizable value assumptions.
Inventory impairments during the first quarter of 2024 of
$0.5 million were associated with
charges related to reductions in net realizable value of dried
cannabis under the Company's product specifications and
obsolescence of certain retired products and packaging, a decrease
of $0.2 million from the comparative
period.
Total Expenses
Selling, general and administrative expenses ("SG&A") are
comprised of wages and benefits, office and administrative,
professional fees, business development, and selling expenses.
SG&A expenses were $8.6 million
in the first quarter of 2024, $1.5
million or 15% lower than the same period in 2023, primarily
due to measures taken to reduce overhead in the organization.
Wages and benefits were $4.3
million for the first quarter of 2024, as compared to
$4.7 million for the same period of
2023. The decrease in expenses was related to the streamlining of
operations and support staff as a result of a more focused product
portfolio.
Office and administrative expenses were $1.4 million for the first quarter of 2024,
$0.9 million lower than the same
period in 2023. The decreased expenditures primarily relate to
streamlining of operations, the transition of the Company's dried
flower and pre-roll cannabis product manufacturing, processing and
distribution activities to the Auxly Leamington facility, and
reduced insurance expenses.
Auxly's professional fees were $0.5
million during the first quarter of 2024, $0.3 million lower than the same period in 2023.
Professional fees incurred primarily related to accounting fees,
regulatory matters, reporting issuer fees, and legal fees
associated with certain corporate activities and as a result can
fluctuate significantly from one period to the next.
Business development expenses were $0.1
million for the first quarter of 2024, flat to the same
period in 2023. These expenses primarily relate to business
development and travel related expenses.
Selling expenses were $2.4 million
for the first quarter of 2024, an increase of $0.1 million over 2023, primarily as a result of
higher Health Canada fees related to higher revenues, partially
offset by reduced marketing initiatives.
Equity-based compensation for the first quarter of 2024 was
$1.9 million, primarily due to the
impact of the increased closing price of the Company's Shares as at
March 31, 2024 on the value of Cash
Settled RSUs. In the first quarter of 2023, equity-based
compensation was $0.4 million.
Depreciation and amortization expenses were $1.2 million for the first quarter of 2024,
representing a decrease of $0.5
million over the same period in 2023, primarily as a result
of reductions in intangible assets and depreciation associated with
disposed assets, including the transition out of the Auxly Ottawa
Carleton Place facility.
Interest expenses were $6.9
million for the first quarter of 2024, an increase of
$1.1 million over the same period in
2023. The increase in expense is primarily a result of the interest
from newly financed obligations and higher accretion expense on
convertible debentures. Interest expense includes accretion on the
convertible debentures and interest paid in kind on the Imperial
Debenture. Interest payable in cash was approximately $2.3 million for the first quarter of 2024, an
increase of $0.3 million over the
same period in 2023.
Total Other Incomes and Losses
Total other incomes and losses for the first quarter of 2024
were a net loss of $0.8 million
compared to a net loss of $0.1
million in the comparative period. Other incomes and losses
in the first quarter of 2024 were mainly driven by the loss on the
adjustment to the provision related to the claim filed by Kindred
Partners Inc. and foreign exchange losses. Other incomes and losses
in 2023 were primarily due to foreign exchange losses.
Net Income and Loss
Net loss for the three months ended March
31, 2024 was $26.0 million,
representing a net loss of $0.03 per
share on a basic and diluted basis. The change in net loss in 2024
as compared to a net loss of $10.2
million in the same period of 2023 was primarily driven by
the deferred tax expense on the conversion of Imperial Debenture
into Shares, partially offset by improved gross profits and lower
expenses.
Adjusted EBITDA
Adjusted EBITDA for the period ended March 31, 2024 was $2.2
million, an improvement of $2.1
million over the same period of 2023, primarily as a result
of improvements in gross profits and SG&A.
Outlook
In 2024, Auxly remains dedicated to sustainable growth, improved
profitability, and the excellence of its people. The Company will
prioritize focused and efficient growth in its key product
categories of vape, pre-roll and dried flower and continue to
optimize and improve distribution and sales of its products. Auxly
will continue to foster a collaborative team environment and pursue
continued improvements in efficiency to reduce costs and deliver
strong gross margins and increased profitability. It will also
continue to pursue opportunities to strengthen its balance
sheet.
Auxly's results for the first quarter of 2024 reinforced its
commitment to sustainable profitability. While the first calendar
quarter of the year is typically impacted by greater seasonality
and consumer purchasing trends, revenues for the quarter improved
from the same comparative period in 2023. This improved result is
due to a more balanced sales mix as its portfolio has expanded
further into dried flower and pre-roll product sales, which
represented approximately 59% of revenues for the period.
Furthermore, vape volumes rebounded in the quarter, building off
the launch of the innovative all-in-one vapes under its Back Forty
brand in Q4 2023. The Company continues to improve its SG&A by
reducing overhead across the organization, ending the first quarter
with $8.6 million in SG&A
expenses, which is 11% lower than Q4 2023 and 15% lower than the
comparative period in 2023. The first quarter of 2024 reflects the
first full quarter of results where it sold certain Cannabis 2.0
Products produced by the Company's contract manufacturing partners,
allowing for the streamlining of its operations and the reduction
of overhead. The Company is pleased to have maintained its
leadership position in the Canadian cannabis market as the
6th largest licensed producer in Canada by total recreational sales, while
maintaining an industry-leading low-cost structure that resulted in
another consecutive quarter of positive Adjusted EBITDA.
Alongside the improvements in revenues, gross margins, and
material improvements in Adjusted EBITDA from the same comparative
period in 2023, the Company continues to strengthen its balance
sheet. Auxly worked closely with Imperial to convert $123.4 million of debt and interest outstanding
under the Imperial Debenture, increasing Imperial's equity holding
in Auxly to 19.8%. The Company also extended the maturity date of
Auxly Leamington's credit facility by two years to December 31, 2025.
Looking ahead, Auxly will continue to grow sustainably and
expect to see revenue expansion and gross margin improvements,
driven by increased consumer demand in the summer months, and
higher cultivation yields that continue to drive down operating
costs. The Company believes that the impact of these factors, along
with the stabilization of its SG&A, will improve its Adjusted
EBITDA profile.
Non- GAAP Measures
Please see the Company's MD&A dated March 24, 2024, under "Non-GAAP Measures" for a
further description of the following financial and supplementary
financial measures.
Financial Measures
EBITDA and Adjusted EBITDA
These are non-GAAP measures used in the cannabis industry and by
the Company to assess operating performance removing the impacts
and volatility of non-cash and other adjustments. The definition
may differ by issuer. The Adjusted EBITDA reconciliation is as
follows:
(000's)
|
Q2/22
|
Q3/22
|
Q4/22
|
Q1/23
|
Q2/23
|
Q3/23
|
Q4/23
|
Q1/24
|
Net
income/(loss)
|
$
(14,289)
|
$
(60,102)
|
$
(16,056)
|
$
(10,249)
|
$
(12,863)
|
$
32,621
|
$
(54,020)
|
$(26,012)
|
Interest and accretion
expense
|
5,336
|
5,507
|
5,655
|
5,808
|
6,457
|
6,613
|
6,837
|
6,868
|
Interest and other
income
|
(84)
|
(105)
|
(63)
|
(14)
|
20
|
(16)
|
(22)
|
(19)
|
Income tax
recovery
|
(85)
|
(2,110)
|
(1,112)
|
-
|
-
|
-
|
(3,238)
|
15,992
|
Depreciation and
amortization
included in cost of sales
|
2,180
|
681
|
1,296
|
1,120
|
911
|
1,151
|
1,084
|
1,292
|
Depreciation and
amortization
included in expenses
|
3,900
|
3,525
|
2,791
|
1,745
|
1,673
|
1,817
|
1,708
|
1,230
|
EBITDA
|
(3,042)
|
(52,604)
|
(7,489)
|
(1,590)
|
(3,802)
|
42,186
|
(47,651)
|
(649)
|
|
|
|
|
|
|
|
|
|
Impairment of
inventory
|
1,778
|
2,014
|
2,062
|
673
|
1,459
|
3,233
|
5,109
|
456
|
Unrealized fair value
loss/(gain)
on biological transformation
|
(11,735)
|
(7,496)
|
(2,814)
|
(4,247)
|
(4,713)
|
(4,766)
|
(2,481)
|
(2,773)
|
Realized fair value
loss/(gain)
on inventory
|
6,898
|
8,175
|
7,382
|
4,639
|
3,146
|
5,538
|
5,428
|
2,435
|
Restructuring related
costs
|
-
|
193
|
-
|
165
|
86
|
29
|
131
|
-
|
Equity-based
compensation
|
2,916
|
475
|
429
|
409
|
377
|
707
|
148
|
1,927
|
Impairment of
assets
|
-
|
42,831
|
676
|
-
|
2,588
|
-
|
37,118
|
-
|
Non-recurring bad debt
expense
|
-
|
-
|
-
|
-
|
780
|
360
|
-
|
-
|
(Gain)/loss on
settlement of
assets, liabilities and disposals
|
(163)
|
1,574
|
(1,330)
|
-
|
(1,478)
|
(46,887)
|
4,006
|
634
|
Foreign exchange
loss/(gain)
|
(647)
|
(938)
|
301
|
89
|
479
|
(283)
|
486
|
210
|
Adjusted
EBITDA
|
$
(3,995)
|
$
(5,776)
|
$ (783)
|
$
138
|
$
(1,078)
|
$
117
|
$ 2,294
|
$
2,240
|
Supplementary Financial
Measures
Gross Margin on Finished Cannabis Inventory Sold
"Gross Margin on Finished Cannabis Inventory Sold" is a
supplementary financial measure and is defined as net revenues less
cost of finished cannabis inventory sold divided by net
revenues.
Gross Profit Margin
"Gross Profit Margin" is defined as gross profit divided by net
revenues. Gross Profit Margin is a supplementary financial
measure.
Debt
"Debt" is defined as current and long-term debt and is a
supplementary financial measure. It is a useful measure in managing
the Company's capital structure and financing requirements.
ON BEHALF OF THE BOARD
"Hugo Alves" CEO
About Auxly Cannabis Group Inc.
(TSX: XLY)
Auxly is a leading Canadian consumer packaged goods company in
the cannabis products market, headquartered in Toronto, Canada. Our mission is to help
consumers live happier lives through quality cannabis products that
they trust and love.
Our vision is to be a leader in branded cannabis products that
deliver on our consumer promise of quality, safety and
efficacy.
Learn more at www.auxly.com and stay up to date at Twitter:
@AuxlyGroup; Instagram: @auxlygroup; Facebook:
@auxlygroup; LinkedIn: company/auxlygroup/.
Investor Relations:
For investor enquiries please contact our Investor Relations
Team:
Email: IR@auxly.com
Phone: 1.833.695.2414
Notice Regarding Forward Looking Information:
This news release contains certain "forward‐looking information"
within the meaning of applicable Canadian securities law.
Forward‐looking information is frequently characterized by words
such as "plan", "continue", "expect", "project", "intend",
"believe", "anticipate", "estimate", "may", "will", "potential",
"proposed" and other similar words, or information that certain
events or conditions "may" or "will" occur. This information is
only a prediction. Various assumptions were used in drawing the
conclusions or making the projections contained in the
forward‐looking information throughout this news release.
Forward‐looking information includes, but is not limited to: the
proposed operation of Auxly, its subsidiaries and
partners; the intention to grow the business, operations and
existing and potential activities of Auxly; proposed timelines
for the build‐out, expansion, licencing or commercialization of the
Company's facilities and projects; the Company's execution of its
innovative product development, commercialization strategy and
expansion plans; the Company's intention to introduce innovative
new cannabis products to the market and the timing thereof; the
anticipated benefits of the Company's partnerships, research and
development initiatives and other commercial arrangements; the
intention of the Company to sell the Auxly Ottawa assets and
the proposed use of any proceeds; expectations regarding the
anticipated benefits of the Imperial Debt Conversion; the
expectation, timing and quantum of future revenues, Gross Margin on
Finished Cannabis Inventory Sold, SG&A and of positive Adjusted
EBITDA; expectations regarding the Company's expansion of sales,
operations and investment into foreign jurisdictions; future
legislative and regulatory developments involving cannabis and
cannabis products; the timing and outcomes of regulatory or
intellectual property decisions; the ability of the Company to
maintain and grow its market share; the relevance of Auxly's
subsidiaries' current and proposed products with provincial
purchasers and consumers; consumer preferences; political change;
competition and other risks affecting the Company in particular and
the cannabis industry generally.
A number of factors could cause actual results to differ
materially from a conclusion, forecast or projection
contained in the forward‐looking information in this release
including, but not limited to, whether: the Company will be able to
execute on its business strategy or achieve its goals; Auxly's
subsidiaries are able to maintain the necessary governmental and
regulatory authorizations to conduct business; the
Company is able to successfully manage the integration
of its various business units with its own; the Company's
subsidiaries obtain and maintain all necessary
governmental and regulatory permits and approvals for the operation
of their facilities and the development of cannabis products, and
whether such permits and approvals can be obtained in a
timely manner; the Company will be able to sell the Auxly Ottawa
assets and achieve the anticipated cost savings from the closure of
the facility; the expected benefits of the Imperial Debt Conversion
materialize in the manner expected, or at all; the expected
benefits of the Auxly Leamington credit facility amendment
agreement materialize in the manner expected, or at all; the
Company will be able to successfully launch new product formats and
enter into new markets; there is acceptance and demand for current
and future Company products by consumers and provincial
purchasers; the Company will be able to increase and maintain
revenues, maintain positive Adjusted EBITDA, and/or achieve and
maintain its target Gross Margin on Finished Cannabis Inventory
Sold; and general economic, financial market, legislative,
regulatory, competitive and political conditions in which the
Company and its subsidiaries and partners operate will remain the
same. Additional risk factors are disclosed in the annual
information form of the Company for the financial year ended
December 31, 2023 dated March 24, 2024.
New factors emerge from time to time, and it is not possible for
management to predict all of those factors or to assess in advance
the impact of each such factor on the Company's business or the
extent to which any factor, or combination of factors, may cause
actual results to differ materially from those contained in any
forward‐looking information. The forward‐looking information in
this release is based on information currently available and what
management believes are reasonable assumptions. Forward‐ looking
information speaks only to such assumptions as of the date of this
release. In addition, this release may contain forward‐looking
information attributed to third party industry sources, the
accuracy of which has not been verified by the Company. The
forward‐looking information is being provided for the purposes of
assisting the reader in understanding the Company's financial
performance, financial position and cash flows as at and for
periods ended on certain dates and to present information about
management's current expectations and plans relating to the future,
and the reader is cautioned that such forward‐ looking information
may not be appropriate for any other purpose. Readers should not
place undue reliance on forward‐looking information contained in
this release.
The forward‐looking information contained in this release is
expressly qualified by the foregoing cautionary statements and is
made as of the date of this release. Except as may be required by
applicable securities laws, the Company does not undertake any
obligation to publicly update or revise any forward‐ looking
information to reflect events or circumstances after the date of
this release or to reflect the occurrence of unanticipated events,
whether as a result of new information, future events or results,
or otherwise.
Neither Toronto Stock Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the Toronto
Stock Exchange) accepts responsibility for the adequacy or accuracy
of this release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/auxly-reports-record-first-quarter-2024-financial-results-302143064.html
SOURCE Auxly Cannabis Group Inc.